Amniotic Membrane Market

Amniotic Membrane Market by Type (Dehydrated Amniotic Membranes and Cryopreserved Amniotic Membranes), Appication (Surgical Wounds, Ophthalmic Disorders, and Others), End-User (Hospitals, Ambulatory Surgical Centres, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing cases of chronic wounds such as burn injuries and trauma cases, increasing cases of ophthalmic disorders such as dry eye, keratitis, among others, and increasing product development activities among the key market players.

The amniotic membrane market was valued at USD 1,096.03 million in 2024, growing at a CAGR of 7.33% during the forecast period from 2025 to 2032 to reach USD 1,922.33 million by 2032. The market for amniotic membrane products is witnessing significant growth, driven by a combination of factors. Increasing cases of chronic wounds, such as burns and trauma, are creating a high demand for effective wound healing solutions. Additionally, the rise in ophthalmic disorders like dry eye and keratitis is expanding the use of amniotic membranes in eye care. These clinical needs, coupled with robust product development initiatives by key market players, are collectively accelerating innovation and adoption, thereby boosting the overall market growth for amniotic membrane-based therapies. Moreover, the membrane’s natural anti-inflammatory and regenerative properties further enhance its appeal across a range of medical applications. Growing awareness among healthcare providers and patients about its clinical benefits is also fueling demand globally. Collectively, these trends are fueling the expansion of the amniotic membrane market worldwide during the forecast period from 2025 to 2032.

Amniotic Membrane Market Dynamics:

According to the World Health Organization (2023), approximately 20 to 50 million people suffer from non-fatal road traffic injuries annually. Road accidents often lead to severe injuries involving soft tissue damage, burns, and complex orthopedic wounds, which require more than conventional wound care for effective recovery. Amniotic membrane, rich in growth factors, cytokines, anti-inflammatory agents, and stem cells, offers a powerful solution for promoting accelerated healing, reducing inflammation, and minimizing scarring.

Additionally, according to the data provided by the International Diabetes Federation (2024), in 2024, approximately 589 million adults were living with diabetes. Diabetic patients are more prone to develop diabetic foot ulcers. As per a recent study (2023), approximately 18.6 million individuals worldwide develop diabetic foot ulcers annually. Amniotic membranes promote tissue regeneration, reduce inflammation, and lower the risk of infection and amputation in diabetic foot ulcer patients, thereby boosting the overall market of amniotic membranes across the globe.

Moreover, the increasing global volume of ophthalmic disorders such as dry eyes, keratitis, glaucoma, cataracts, and corneal ulcers are significantly propelling the demand for amniotic membranes. According to the data provided by the University Hospitals Organization (2024), nearly 300 million people worldwide experience dry eye. An estimated 3.2 million women aged 50 and over, and 1.68 million men aged 50 and over were affected by dry eye. Dry eye disease is a chronic condition characterized by inflammation, ocular surface damage, and tear film instability, leading to discomfort and vision disturbances. Traditional treatments like artificial tears and anti-inflammatory drops often provide only temporary relief. Amniotic membranes, especially cryopreserved or dehydrated forms, offer a biologically active solution rich in growth factors, anti-inflammatory cytokines, and extracellular matrix proteins that help regenerate the damaged ocular surface, reduce inflammation, and restore tear film stability. These membranes can be applied as sutureless grafts or self-retaining devices like Prokera®, delivering therapeutic benefits directly to the eye.

According to the data provided by DelveInsight Business Research LLP (2024), in 2023, the prevalence of Neurotrophic Keratitis (NK) was highest in the US among the 7MM, accounting for nearly 66 thousand cases which was further expected to increase by 2034. NK is a rare, degenerative corneal disease caused by damage to the trigeminal nerve, leading to reduced corneal sensitivity, poor wound healing, and progressive corneal ulceration or perforation. Traditional therapies such as artificial tears and ointments often fail to provide adequate regeneration of the corneal epithelium. In contrast, amniotic membranes, rich in growth factors, anti-inflammatory proteins, and extracellular matrix components, offer a regenerative platform that accelerates corneal healing, reduces inflammation, and prevents scarring.

The increase in product development activities by key market players is significantly boosting the overall market for amniotic membranes. For instance, in June 2024, Axogen, Inc. launched Avive+ Soft Tissue Matrix™, a resorbable, multi-layer amniotic membrane allograft designed as a soft tissue barrier for peripheral nerve healing. The product was processed and distributed in compliance with FDA and state regulations as a 361 human tissue product.

However, the competition from alternative products and the limited shelf life of cryopreserved, among others are some of the key constraints that may limit the growth of the amniotic membrane market.

Amniotic Membrane Market Segment Analysis:

Amniotic Membrane Market by Type (Dehydrated Amniotic Membranes and Cryopreserved Amniotic Membranes), Application (Surgical Wounds, Ophthalmic Disorders, and Others), End-User (Hospitals, Ambulatory Surgical Centres, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the type segment of the amniotic membrane market, the devices category is estimated to account for the largest market share in 2024. Dehydrated amniotic membranes, are playing a vital role in boosting the overall amniotic membrane market due to their extended shelf life, ease of storage and transport, and growing clinical adoption across a range of therapeutic areas. Unlike cryopreserved variants, dehydrated amniotic membranes do not require refrigeration or specialized storage, making them highly convenient for use in outpatient clinics, surgical centers, and remote healthcare settings especially in developing regions with limited cold chain infrastructure.

These membranes retain many of the essential biological properties of the native amniotic tissue, including anti-inflammatory, anti-fibrotic, and pro-regenerative characteristics, though some cellular components may be compromised during processing. Nevertheless, dHAM products are proving to be highly effective in managing chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers, and surgical wounds, as well as in ophthalmic applications like corneal defects and conjunctival reconstruction.

Dehydrated amniotic membranes (dHAMs) are rich in cytokines and growth factors that play a crucial role in reducing inflammation and modulating the immune response. These properties make them particularly effective in the treatment of chronic wounds and autoimmune-related conditions. In addition to their therapeutic benefits, dHAMs offer practical advantages: their widespread availability and room-temperature stability eliminate the need for frozen storage, making them a convenient, ready-to-use biologic solution for clinicians across various care settings.

Additionally, the increase in product development activities across the globe is further boosting the overall market of dehydrated amniotic membranes. For instance, in January 2023, MiMedx Group, Inc. entered into an exclusive distribution agreement with Gunze Medical Limited for the sales of EPIFIX dehydrated human amnion/chorion membrane allografts in Japan. Gunze Medical, a subsidiary of Gunze Limited, is a leading distributor of wound and surgical products.

Together, these above mentioned factors are fueling the increasing demand for dehydrated amniotic membranes, thereby propelling the growth of the overall expansion of the amniotic membrane market during the forecast period from 2025 to 2032.

North America is expected to dominate the overall amniotic membrane market:

North America is projected to hold the largest share of the amniotic membrane market in 2024, driven by several key factors. The market is driven by the rising prevalence of chronic wounds and ophthalmic disorders. Additionally, advanced healthcare infrastructure and the strong presence of key market players leading to increased product development activities are boosting the overall market of amniotic membranes.

As per the data from the National Institute of Health (2023), approximately 1.6 million people were living with diabetic foot ulcers in the United States. DFUs are chronic, non-healing wounds that result from a combination of neuropathy, poor circulation, and immune dysfunction, and they pose a high risk of infection, hospitalization, and amputation. Amniotic membranes, derived from human placental tissue, offer unique biological properties that make them highly effective in treating chronic wounds like DFUs. They are rich in growth factors, cytokines, and extracellular matrix components that support cell proliferation, modulate inflammation, and promote tissue regeneration thereby boosting the overall market across the region.

Additionally, according to the data provided by DelveInsight Business Research LLP (2023), approximately, ~13 thousand males and ~19 thousand females were affected with neurotrophic keratopathy. It is a corneal condition caused by trigeminal nerve damage leading to impaired corneal healing. The amniotic membrane promotes healing in cases where nerve regeneration is compromised thus escalating the overall market across the region.

Additionally, as per the same source, in 2023, about 22,475 thousand cases of dry eye diseases were reported in the United States. The amniotic membrane provides lubrication, reduces inflammation, and supports surface restoration for dry eye patients thereby boosting the overall market of amniotic membrane across the region.

Market growth in the U.S. is further supported by innovation from key players. For example, in July 2023, Celularity Inc. and Verséa Health, Inc. entered into an exclusive U.S. commercialization agreement under which Verséa distributed Celularity’s BIOVANCE® and BIOVANCE® 3L Ocular products. These single-layer and three-layer amniotic membrane allografts were used as biological membranes to support ocular surface disease treatment and surgical applications. BIOVANCE® 3L Ocular, an acellular product, provided tissue protection and helped preserve tissue plane boundaries.

Together, these factors are expected to significantly drive the growth of the amniotic membrane market in North America during the forecast period from 2025 to 2032.

Amniotic Membrane Market Key Players:

Some of the key market players operating in the amniotic membrane market include BioTissue, Inc., Corza Ophthalmology, Integra LifeSciences, Merakris Therapeutics, Inc., Seed Biotech, Inc., Atlas Ocular, BioLab Holdings, Inc., Orthofix Medical Inc., Labtician Ophthalmics Inc., Smith & Nephew, Organogenesis Inc., Celularity Inc., Tides Medical, StimLabs, MIMEDX Group, Inc., NuVision Biotherapies Ltd., Next Biosciences, Sanara MedTech Inc., Axogen Corporation, Dynamic Medical Services DBA Acesso Biologics, and others.

Recent Developmental Activities in the Amniotic Membrane Market:

• In April 2025, BioTissue Inc. announced that the new research will be presented at the 2025 American Urological Association Conference in Las Vegas which evaluated robotic ureteral reconstruction using Clarix® 1K, an ultra-thick cryopreserved amniotic membrane by BioTissue Surgical. In a study of 17 patients, 88% showed symptomatic improvement and 76% had radiographic improvement at one-year follow-up. Researchers concluded that Clarix® 1K was a safe and effective alternative to autologous grafts for medium-length ureteral strictures.
• In November 2024, Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island.
• In October 2024, Merakris Therapeutics launched Dermacyte AC Matrix, a lyophilized amnion-chorion membrane allograft, at the Fall Symposium for Advanced Wound Care in Las Vegas. The product featured multiple membrane layers and an optimized bioprocess, offering better protein retention and maintaining key physical and biological properties of placental membranes.
• In June 2024, BioTissue Inc., launched CAM360 AG, a hydrated, shelf-stable cryopreserved amniotic membrane, as a ringless, no-refrigeration solution ideal for mild to moderate dry eye and ocular surface conditions. Its adhesive properties helped it stay in place under a bandage contact lens, enhancing comfort and treatment.
• In June 2024, Axogen, Inc. launched Avive+ Soft Tissue Matrix™, a resorbable, multi-layer amniotic membrane allograft designed as a soft tissue barrier for peripheral nerve healing. The product was processed and distributed in compliance with FDA and state regulations as a 361 human tissue product.

Key takeaways from the amniotic membrane market report study

• Market size analysis for current amniotic membrane market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the amniotic membrane market.
• Various opportunities available for the other competitors in the amniotic membrane market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current amniotic membrane market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for amniotic membrane market growth in the coming future?

Target audience who can benefit from this amniotic membrane market report study

• Amniotic membrane product providers
• Research organizations and consulting companies
• Amniotic membrane-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in amniotic membrane
• Various end-users who want to know more about the amniotic membrane market and the latest technological developments in the amniotic membrane market. 

Frequently Asked Questions for the Amniotic Membrane Market:

1. What are amniotic membrane?

• The amniotic membrane is the innermost layer of the placenta, composed of a thin, avascular tissue rich in collagen and growth factors. It is widely used in medical applications for its anti-inflammatory, anti-scarring, and wound-healing properties, particularly in wound care, ophthalmology, and regenerative medicine.

2. What is the market for amniotic membrane?

• The amniotic membrane market was valued at USD 1,096.03 million in 2024, growing at a CAGR of 7.33% during the forecast period from 2025 to 2032 to reach USD 1,922.33 million by 2032.

3. What are the drivers for the amniotic membrane market?

• The market for amniotic membrane products is witnessing significant growth, driven by a combination of factors. Increasing cases of chronic wounds, such as burns and trauma, are creating a high demand for effective wound healing solutions. Additionally, the rise in ophthalmic disorders like dry eye and keratitis is expanding the use of amniotic membranes in eye care. These clinical needs, coupled with robust product development initiatives by key market players, are collectively accelerating innovation and adoption, thereby boosting the overall market growth for amniotic membrane-based therapies. Moreover, the membrane’s natural anti-inflammatory and regenerative properties further enhance its appeal across a range of medical applications. Growing awareness among healthcare providers and patients about its clinical benefits is also fueling demand globally. Collectively, these trends are fueling the expansion of the amniotic membrane market worldwide during the forecast period from 2025 to 2032.

4. Who are the key players operating in the amniotic membrane market?

• Some of the key market players operating in the amniotic membrane market include BioTissue, Inc., Corza Ophthalmology, Integra LifeSciences, Merakris Therapeutics, Inc., Seed Biotech, Inc., Atlas Ocular, BioLab Holdings, Inc., Orthofix Medical Inc., Labtician Ophthalmics Inc., Smith & Nephew, Organogenesis Inc., Celularity Inc., Tides Medical, StimLabs, MIMEDX Group, Inc., NuVision Biotherapies Ltd., Next Biosciences, Sanara MedTech Inc., Axogen Corporation, Dynamic Medical Services DBA Acesso Biologics, and others.

5. Which region has the highest share in the amniotic membrane market?

• North America is projected to hold the largest share of the amniotic membrane market in 2024, driven by several key factors. The market is driven by the rising prevalence of chronic wounds and ophthalmic disorders. Additionally, advanced healthcare infrastructure and the strong presence of key market players leading to increased product development activities are boosting the overall market of amniotic membranes.